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Summary Four poly(ADP-ribose) polymerase (PADPRP) inhibitors [3-aminobenzamide, benzamide, 3,4-
dihydro-5-methoxyisoquinolin-1(2H)-one (PD 128763) and 8-hydroxy-2-methylquinazolin-4(3H)-one
(NU1025)] were compared with respect to their effects on a number of biological end points. The following
parameters were assessed: their ability to inhibit the enzyme in permeabilised L1210 cells; their ability to
potentiate the cytotoxicity of temozolomide (including the cytotoxicity of the compounds per se); their ability
to increase net levels of temozolomide-induced DNA strand breaks and inhibit temozolomide-induced NAD
depletion. PD 128763 and NU1025 were equipotent as PADPRP inhibitors, and 40- and 50-fold more potent
than benzamide and 3-aminobenzamide respectively. All the compounds acted in a concentration-dependent
manner to potentiate the cytotoxicity and increase DNA strand break levels in cells treated with
temozolomide. There was an excellent correlation between the potency of the compounds as PADPRP
inhibitors and their effects on cell survival and DNA repair. Temozolomide treatment caused a decrease in
cellular NAD levels, and this was abolished by the PADPRP inhibitors. In conclusion, the new generation of
PADPRP inhibitors are at least 50-fold more effective than 3-aminobenzamide as chemopotentiators, and can
be used at micromolar rather than millimolar concentrations in intact cells.
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Poly(ADP-ribose) polymerase (PADPRP, EC 2.4.2.30) is an
abundant chromatin-bound enzyme which is activated by
DNA strand breaks. PADPRP function has been implicated
in a variety of biological processes, including DNA repair
and cellular survival following DNA damage, recombination
and regulation of gene expression and development (for
reviews see Boulikas, 1991; de Murcia and Menissier-de Mur-
cia, 1994). Although the role of PADPRP is best understood
in DNA repair, this is still an area of contention regarding
the precise molecular mechanisms involved. Two general
mechanisms have been proposed, based on accumulated
evidence. Poly(ADP-ribose) synthesis leads to a dramatic
structural modification of chromatin, resulting from the
electrostatic repulsion of the negatively charged covalently
modified proteins (mainly PADPRP itself and histones) from
the DNA. This may allow access of repair enzymes to
damaged sites on DNA (Althaus et al., 1993). Alternatively,
unmodified PADPRP binds tightly to free DNA ends, thus
preventing further processing; upon automodification, PAD-
PRP is released from DNA, allowing gap filling and ligation
to occur (Satoh and Lindahl, 1992). An additional function
of poly(ADP-ribose) synthesis may be to modulate directly
the activity or function of covalently modified acceptor pro-
teins (enzymes, transcription factors). For example, poly
(ADP-ribosylation) of DNA polymerases, ligase and topo-
isomerase I causes inhibition of these enzymes in vitro (Ferro
et al., 1983; Yoshihara et al., 1985). However, little work has
been carried out to establish whether these proteins can act
as acceptors in intact cells.
A range of PADPRP inhibitors, of which 3-amino-
benzamide (3AB) has been the most widely used, was first
developed by Purnell and Whish (1980). The demonstration
that they could modulate cellular DNA repair and survival
responses (Durkacz et al., 1980) has led to a search for more
potent inhibitors for use in cancer chemotherapy (Suto et al.,
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1991; Banasik et al., 1992). There has been a long-standing
dispute concerning the specificity of benzamide and its
derivatives as PADPRP inhibitors (particularly regarding
their effects on de novo purine synthesis), and thus about the
interpretation of the biological data (e.g. Hunting et al.,
1985; Moses et al., 1990). Nevertheless, the literature span-
ning 15 years portrays a remarkable consistency regarding
their effects. Thus, PADPRP inhibitors, at concentrations
which are not cytotoxic per se, inhibit ADP-ribose polymer
synthesis in intact cells (Rankin et al., 1989). They retard the
rejoining of DNA strand breaks and potentiate the cytotox-
icity of a range of DNA-damaging agents (e.g. Durkacz et
al., 1980). PADPRP activation by DNA strand breaks causes
cellular NAD depletion which is abrogated by PADPRP
inhibitors (Durkacz et al., 1980). The increased levels of
DNA strand breaks obtained in the presence of PADPRP
inhibitors has been assumed to be a consequence of inhibi-
tion of a late stage in the repair process (e.g. ligation,
Creissen and Shall, 1982).
In more recent years, this scenario of events modulated by
PADPRP function following DNA damage has been further
substantiated by molecular, genetic and in vitro approaches
to PADPRP function. Mutant cell lines which are deficient in
PADPRP activity have been isolated by a number of
different techniques (Maclaren et al., 1990; Chatterjee et al.,
1991; Witmer et al., 1994). These cell lines are typified by
their hypersensitivity to monofunctional alkylating agents.
Cell lines transfected with and overproducing the 'DNA
binding domain' (DBD) of PADPRP, thus inhibiting
endogenous PADPRP activation, are also hypersensitive to
monofunctional alkylating agents, and are unable to carry
out unscheduled DNA synthesis (Molinette et al., 1993).
Similar results have been obtained by reducing endogenous
PADPRP synthesis by the use of antisense olignucleotides to
PADPRP (Smulson et al., 1994). Finally, elegant in vitro
experiments using crude cell extracts which can carry out
DNA repair have established that PADPRP, in the absence
of substrate, blocks DNA strand breaks snd prevents subse-
quent steps leading to religation of the DNA (Satoh and
Lindhal, 1992; Satoh et al., 1993).
PADPRP inhibitors have the potential to act as resistance
modifiers when used in conjunction with radiation or
chemotherapeutic agents. However, very little in vivo workPotentiation of temozolomide cytotoxicity
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has been carried out to assess their capacity to increase the
therapeutic index of anti-cancer drugs, mainly because ben-
zamide and its derivatives lacked sufficient potency and were
of low solubility. Recently, more potent PADPRP inhibitors
have been identified (e.g. Suto et al., 1991), but limited work
has been carried out to establish their biological efficacy.
We have developed an evaluation system to compare can-
didate compounds with respect to their potency as PADPRP
inhibitors and their effectiveness as chemopotentiators in
intact cells. Two 'classical' inhibitors, benzamide (BZ) and
3AB, have been compared with 3,4-dihydro-5-methoxyiso-
quinolin-1(2H)-one (PD 128763), developed by Warner
Lambert (Suto et al., 1991), and 8-hydroxy-2-methyl-
quinazolin-4(3H)-one (NU1025). NU1025 was synthesised in
the Department of Chemistry, University of Newcastle upon
Tyne (Griffin et al., 1995), as part of an ongoing programme
to design new PADPRP inhibitors. PD 128763 (100 mg kg-')
has been shown to be a highly active radiosensitiser in vivo,
causing > 50% reduction in tumour burden in mice bearing
subcutaneous implants of SCC7 cells (Leopold and Sebolt-
Leopold, 1992). The structures of the PADPRP inhibitors are
shown in Figure 1 for comparison.
A chemotherapeutically relevant alkylating agent,
temozolomide (TM, see Figure 1 for structure; Stevens et al.,
1987), which has shown promising results in phase I clinical
trials (Newlands et al., 1992), was used in these studies. TM
breaks down in biological milieu to MTIC [5-(3-methyl-
triazen-1-yl)imidazole-4-carboxamide], and thence to the
methyldiazonium ion, which directly methylates bases in
DNA (Denny et al., 1994).
In the body of work described here, we have used TM, in
conjunction with the PADPRP inhibitors, to investigate the
PADPRP-mediated repair and survival responses in murine
leukaemia L1210 cells. The results demonstrate an excellent
correlation between in vitro potency of the compounds as
PADPRP inhibitors, and their ability to modulate cellular
responses induced by DNA damage.
Materials and methods
Drugs and chemicals
3AB was obtained from Pfaltz and Bauer, Phase Separations,
Deeside, UK; BZ from Sigma, St Louis, MO, USA; TM was
a gift from MFG Stevens, Cancer Research Laboratories,
University of Nottingham. The methodology for the syn-
thesis of NU1025 is described elsewhere (RJ Griffin et al.,
1995). PD 128763 was a gift from WR Leopold, Parke-Davis
Pharmaceutical Division, Warner Lambert, Ann Arbor, MI,
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Figure 1 Structures of PADPRP inhibitors and temozolomide.
USA. Stock solutions of 3AB and BZ were prepared by
dissolving in complete medium and filter sterilising. NU1025
and PD 128763 were dissolved in dimethyl sulphoxide
(DMSO) and added to cell culture at a final concentration of
K 1% DMSO. [32P]NAD (1000 Ci mmol 1), [methyl-3H]TdR
(41 Ci mmol-') and [2-'4C]TdR (52 mCi mmol-') were pur-
chased from Amersham International (Amersham, UK).
Cell culture, growth inhibition and clonogenic survival assays
The murine leukaemia L1210 cell line was maintained as a
suspension culture in RPMI-1640 medium supplemented with
10% fetal calf serum, glutamine (2 mM) and antibiotics
(penicillin, 100 U ml-'; streptomycin, 100fig ml 1). Hepes
and sodium bicarbonate were added at final concentrations
of 18 mM and 11 mM respectively. Cell densities were
routinely maintained between 1 x 104 and 8 x 105ml-'.
Growth inhibition experiments were used to assess the
cytostatic effects of the compounds. Cells were seeded at
1 x I04ml-' in triplicate in 24-well multidishes. After 24 h
drugs were added in the combinations and at the concentra-
tions specified in the figure legends. At this time one set of
replicates was counted using a Coulter counter (No). After
48 h the remaining samples were counted (N,). The percen-
tage growth inhibition of drug-treated samples was estimated
as N, - No (drug treated)/N,- No (control) x 100. In drug
combination experiments, in which evidence of synergistic
effects on cell growth or clonogenicity (see below) was being
sought, the single, fixed concentration drug sample was taken
as the control value (N, control) in the above equation.
Clonogenic survival assays were used to assess the cytotox-
icity of the compounds. They were performed as previously
described (Sebolt-Leopold and Scavone, 1992), except that
colonies were counted by eye on a gridded light box. The
drug treatment protocols are described in the figure legends,
and were carried out in suspension culture before plating the
cells in agar, in the absence of drugs, to estimate survival.
Survival and growth inhibition curves show the mean of
three independent experiments ± s.e. Where error bars are
not displayed in the figures, it is because they are obscured
by the symbols.
PADPRP assays
PADPRP activity was measured in a permeabilised cell assay.
L1210 cells were rendered permeable to exogenous [32P]NAD
by exposure to hypotonic buffer and cold shock, as described
by Halldorsson et al. (1978). In order to reveal total available
enzyme activity, a palindromic dodecanucleotide, which
forms a short double-stranded hairpin loop with a blunt end
demonstrated to activate PADPRP (Grube et al., 1991), was
included in the assay at a concentration of 20jigml-'. Fol-
lowing incubation of the permeabilised cells with [32P]NAD,
incorporation of 32p into acid precipitable counts was
estimated. The results are expressed as percentage activity of
the drug-treated relative to the control samples, and are the
mean of quadruplicate samples ± s.e.
NAD assays
Cellular NAD levels were determined by a modification of
the method of Nisselbaum and Green (1969). Cells were
treated with drugs at the concentrations and for the times
specified in the figure legends. Approximately 5 x 106 cells
per sample were harvested at 4°C, washed once with ice-cold
phosphate-buffered saline (PBS) and repelleted. The pellet
was resuspended in 1.0 ml of 50% (v/v) ethanol and
sonicated for 20 s. An aliquot was removed for protein
estimation (Bradford, 1976), and then the suspension was
centrifuged for 2 min in a microfuge. The supernatant liquid
was used for NAD assays as described. Results are expressed
as pmol NAD mg-I protein, and represent the average of
three independent samples ± s.e.DNA strand break assays
DNA strand-break levels were assessed using the technique
of Kohn et al. (1981). Cells were prelabelled with
0.4yCi ml-' [14C]TdR for 24 h, followed by a 6 h chase in
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Figure 2 Effect of inhibitors on PADPRP activity in a
permeabilised cell assay. Results are expressed as percentage
inhibition ofenzyme activity in the presence ofincreasing concen-
trations of inhibitors. (*) PD 128763; (0) NU1025; (0) BZ;
(A) 3AB.
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non-radioactive medium. Cells were then exposed to drugs at
the concentrations and for the times specified in the figure
legends. Internal standards were similarly labelled with
1 lsCi ml- [3H]TdR, exposed to 300 cGy, then loaded on the
same filters as the drug treated samples, and eluted at
pH 12.2. To summarise the data obtained, the results were
expressed using the 'relative elution' (RE) formula of For-
nace and Little (1977). RE represents the amount of DNA
from the treated samples retained on the filter as a ratio of
control (untreated). It is calculated using (log RR,p,k) - (log
RRcontroj), where RR (relative retention) is the fraction of
sample DNA retained on the filter when 50% of the internal
standard DNA has eluted. Points represent six replicates
from three individual experiments ± s.e.
Results
PADPRP assays
The relative potencies of the four compounds studied as
inhibitors of PADPRP are shown in Figure 2, in which
percentage PADPRP inhibition is plotted against compound
concentration. The ICo values of PD 128763 and NU1025 in
this in vitro assay were 0.36 ± 0.01 and 0.44 ± 0.13tLM
respectively. 3AB and BZ were more than an order of mag-
b
[3AB1 (mM) [Benzamide] (mM)
d
0.5 1.0 0.0 0.5
[NU10251 (mM) [PD 1287631 (mM)
Figure 3 The effect of increasing concentrations of PADPRP inhibitors alone (0) or in conjunction with a fixed (100 gM) concentration of TM (0) on cell growth. (a) 3AB. (b) BZ (c) NU1025. (d) PD 128763.
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nitude less potent, with IC50 values of 19.1 ± 5.9 fLM and
13.7 ± 6.9lIM. This approximately 50-fold decrease in the
IC50 value of PD 128763 compared with 3AB is in excellent
agreement with the data of Suto et al. (1991).
Growth inhibition assays
The cytostatic effects of PADPRP inhibitors used alone or in
conjunction with a fixed concentration (1000tM) of TM were
investigated (Figure 3). Exposure ofcells to TM alone caused
inhibition of cell growth, with an IC_0 value of 361 ± 25j4M
(results not shown). Co-exposure of cells to 100jsM TM with
Table I Comparison of the IC50 values of the PADPRP inhibitors
alone or in conjunction with 100 jLM TM estimated from the growth
inhibition experiments
IC50 (mM) ± s.e. IC50 (mM) ± s.e.
Inhibitor inhibitor alone inhibitor+ 1001M TM
3-Aminobenzamide 6.7 ± 0.2 2.5 ± 0.1
Benzamide 2.5 ± 0.3 0.84 ± 0.12
NU1025 0.41 ± 0.06 0.04 ± 0.003
PD 128763 0.45 ± 0.01 0.023 ± 0.002
The IC50 values were derived from the smooth curve analysis of
GraphPad Inplot, San Diego, CA, USA software and were averaged
from at least three independent experiments ± s.e.
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increasing concentrations of PADPRP inhibitors caused a
synergistic increase in growth inhibition (Figure 3). Note that
for these experiments, the growth of cells in 100ILM TM,
which itself reduced growth by about 26%, has been nor-
malised to 100% (see Materials and methods). The IC50
values for the inhibitors alone or in conjunction with 100 AM
TM are summarised in Table I.
Ten to 20-fold higher concentrations of PD 128763 and
NU1025 alone were required to inhibit cell growth than were
required when the compounds were used in conjunction with
100 1M TM. For example, the ICso of NU1025 alone was
0.41 mm, and this was reduced to 0.04 mM in the presence of
TM. In comparison, only 2- to 3-fold differences were
obtained with 3AB and BZ, where there was considerable
overlap between the growth-inhibitory effects of the com-
pounds per se, and their effects in conjunction with TM. The
potency of the compounds as PADPRP inhibitors reflected
their effectiveness as inhibitors of cell growth, although this
does not constitute proof that PADPRP function is essential
for cell growth.
Clonogenic survival assays
It was necessary to establish that growth inhibition actually
reflected cytotoxicity. Clonogenic survival assays were per-
formed, where cells were exposed to increasing concentra-
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Figure 4 The effect of a 16 h exposure of cells to increasing concentrations of TM, in the presence or absence of fixed
concentrations of PADPRP inhibitors, on clonogenic survival (a) *, Control; 0, + 1 mm 3AB; A, + 5 mM 3AB. (b) *, control;
0, + I mm BZ; A, + 3mM BZ. (c), *, control; 0, + IOJgM NU1025; A, +50OiM NU1025; *, + I00 sM NU1025. (d) @,
control; 0, + IOjM PD 128763; A, + 50 #AM PD 128763; *, + 100 iM PD 128763.
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x
-tions of TM for 16 h, either alone or in the presence of fixed
concentrations of PADPRP inhibitors, before plating for
survivors in the absence of drugs. The survival curves are
presented in Figure 4, and the DEFIo values given in Table
II. (DEFIo is the ratio of the concentration of TM that
reduces survival to 10% divided by the concentration of TM
that reduces survival to 10% in the presence of a fixed
concentration of PADPRP inhibitor). It can be seen that
there was a reasonable correlation between growth inhibitory
Table II Comparison of the DEFIO values obtained for a range of
concentrations of the PADPRP inhibitors derived from the
clonogenic assays shown in Figure 4
Inhibitor Concentration DEF,0a
3-Aminobenzamide 1 mM 2.4 0.3
5 mM 4.1 0.4
Benzamide 1 mm 4.0 0.7
3mM 6.9±0.2
NU1025 10fsM 2.0 0.2
50 1M 4.0 0.5
100 tM 5.1±0.7
PD128763 10 tM 2.0 0.1
50 Mm 6.0 0.5
1OOtIM 7.1±0.4
Defl0 values were calculated using the smooth curve analysis
described in Table I. Each value represents the average ± s.e. derived
from the averaged 10% survival for TM alone (675 ± 31 ylM from 22
independent survival curves) divided by individual 10% survival
values from at least three independent survival curves performed in
the presence of a fixed concentration of inhibitor.
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Figure 5 The effect of TM and the PADPRP inhibitors on the
cellular NAD levels. (a) The effects of two fixed concentrations of
TM was followed with time *, 1 mM; *, 2 mM. (b) The effect of
increasing concentrations of PADPRP inhibitors on NAD levels
in cells treated with 2 mM TM for 4 h incubation: A, 3AB; *,
PD 128763.
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and cytotoxic effects for TM alone with an IC50 value of
361 gM ± 25 ILM and a LD50 value of 251 ± 13 tiM, respec-
tively, despite the differing exposure times (48 h for growth
inhibition and 16 h for cytotoxicity). TM has a half-life in
culture of about 40 min (Tsang et al., 1991), and therefore
will exert its full effects well before the minimum duration of
exposure of either experiment. All compounds potentiated
the cytotoxicity of TM, but PD 128763 and NU1025 pro-
duced about the same DEF1o values at approximately 100-
fold and approximately 60-fold lower concentrations than
3AB and BZ respectively (Table II). For example, 5011M
NU1025 and 5 mM 3AB gave equivalent DEFIO values of
approximately 4. For both PD 128763 and NU1025, max-
imal potentiation of cytotoxicity was obtained by concentra-
tions of 50-1I00 AM, and was significant at doses as low as
10LM.
The cytotoxic effects of the compounds alone were also
investigated. The LDm values for a 24 h exposure were
14 ± 1.0 mM (3AB); 6.0 ± 1.5 mM (BZ); 1.6 ± 0.1 mM
(NU1025) and 0.99 ± 0.18 mM (PD 128763) (results not
shown). The LD50 values differed by < 3-fold from the IC50
values, and again reflected their potency as PADPRP
inhibitors. In agreement with the growth inhibition data
there was a > 10-fold difference between the concentrations
of PD 128763 and NU1025 required to produce maximal
potentiation of TM cytotoxicity and the concentrations
required to produce cytotoxicity per se.
NAD assays
Changes in NAD levels are a convenient, albeit indirect,
assessment of PADPRP activation in TM-treated cells.
Figure 5a shows a time-dependent depletion of NAD levels
following treatment with 1 or 2 mM TM. Evidence that the
NAD depletion is mediated by PADPRP activation is shown
in Figure Sb. A 4 h incubation with 2 mM TM caused a 50%
decrease in cellular NAD levels, and this was abrogated in a
concentration-dependent manner by PD 128763 and 3AB.
Note that 10ILM PD 128763 sufficed to prevent approx-
imately 50% of NAD drop, and that NAD depletion was
completely prevented by 100ItM. These data correlate with
the concentration ranges of PD 128763 required to effect
potentiation of cytotoxicity in the clonogenic survival
experiments. In contrast, at least an order of magnitude
higher concentrations of 3AB were required to exert the same
effects on NAD levels in TM-treated cells.
DNA strand break assays
The effect of the PADPRP inhibitors on DNA strand break
levels in TM-treated cells was monitored by alkaline elution.
A 1 h treatment with TM resulted in a concentration-
dependent increase in the rate of elution (results not shown).
Changes in DNA strand break levels were detectable at levels
of TM as low as 150lfM, which reduced survival by about
30%. All the compounds were tested for their ability to
produce strand breaks when used alone. A 24 h incubation of
cells with 1 mM PD 128763 or NU1025 and 20 mM 3AB or
BZ had no effect on DNA strand-break levels compared with
untreated cells (results not shown).
Co-incubation of a fixed concentration of TM (150IM)
with increasing concentrations of all PADPRP inhibitors for
1 h caused a progressive increase in the rate of elution com-
pared with TM alone. A specimen elution profile for the
effect of increasing concentrations of NU1025 on TM-
induced DNA strand break levels is shown in Figure 6. The
results for all four compounds have been summarised by
plotting RE values vs inhibitor concentration, and are shown
in Figure 7. Note that the RE values for TM + inhibitor-
treated cells have been calculated using TM alone controls,
and not untreated cells. For all the compounds, the RE value
increased linearly with increasing concentration. However,
RE values started increasing for PD 128763 and NU1025 at
about 100ylM, whereas concentrations above 3 mm and 5 mM
were required to increase significantly the RE values for BZPotntiation oftemozolomidecytotoxkity
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and 3AB respectively. Again, the potency of the compounds
in the DNA strand break assay demonstrated an excellent
correlation with in vitro PADPRP inhibitory potency.
Finally, the temporal kinetics ofTM-induced DNA strand-
break formation and religation was analysed, and the results
are presented in Figure 8. In cells treated with 200tLM TM,
DNA strand-break levels increased rapidly up to 4 h and
declined thereafter. By 24 h DNA strand break levels had
returned to almost control levels. Both 3AB (5 mM) and
NU1025 (300 J.M) increased net levels of DNA strand breaks
over the entire time period. The time interval during which
DNA strand break levels were highest (approximately 2-4 h)
correlated with the reported timing of the peak levels of
MTIC obtained in culture medium following addition of TM
1.04
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(Tsang et al., 1991). This implies that the breakdown of
MTIC to the methyl diazonium ion, which directly alkylates
DNA, is relatively rapid compared to the decomposition of
TM to MTIC in culture medium. It should be emphasised
that these data do not differentiate between enhanced
incision or reduced ligation as a causative mechanism for the
net increase in DNA strand break levels observed in
inhibitor-treated cells.
Discussion
This is the first report of a comprehensive and quantitative
analysis comparing the effects of a range of PADPRP
inhibitors on PADPRP activity and on the biological end
points associated with the cellular responses to DNA
damage. Suto et al. (1991) and Sebolt-Leopold and Scavone
(1992) demonstrated that PD 128763 potentiated the cytotox-
icity of ionising radiation, the monofunctional alkylating
agent, streptozotocin, and also 2-nitroimidazole. However,
PD 128763 was only used at a concentration of 500 LM in
their experiments, thereby potentially underestimating the
potency of this compound in intact cells. Here we have
established that maximal potentiation of TM is obtained at a
10-fold lower concentration (501tM), and is significant at
concentrations as low as 10gM. However, we cannot rule out
the possibility that the concentration-dependent effects of
PADPRP inhibitors may vary with different DNA-damaging
agents, and in different cell lines.
In phase I trials, following a dose of TM (200 mgm
peak plasma levels of approximately 50JiM were achieved by
2 h (Newlands et al., 1992). These levels are of the same
order of magnitude as the concentration (> 1I 00 .M) used in
our experiments, in which potentiation of cytotoxicity by
PADPRP inhibitors was observed.
The new compounds are about 50-fold more potent as
PADPRP inhibitors than 3AB and BZ, and this differential is
a
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Figure 6 DNA strand-break levels assessed by alkaline elution.
The effect of co-incubation with increasing concentrations of
NU1025 in cells treated with a fixed concentration (150I1M) of
TM for 1 h. *, Control (untreated); *, TM alone; 0,
TM + 0.3 mM NU1025; A, TM + 0.5 mM NU1025; 0,
TM + 1.0 mM NU1025.
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Figure 7 The effect of increasing concentrations of PADPRP
inhibitors on DNA strand-break frequency in cells treated with
150 LM TM for 1 h. In this case RE values have been calculated
as a ratio of the RR values for PADPRP inhibitor-treated cells
over the RR value of TM-treated cells. RE values have been
plotted against increasing inhibitor concentration. *, PD 128763;
0, NU1025; 0, BZ; A, 3AB.
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Figure 8 The effect of 200IM TM ± PADPRP inhibitors on
DNA strand-break levels over a 24 h time course. RE values have
been plotted against time (a) 0, 200tLM TM alone; A, 200tLM
TM + 5mM 3AB. (b) 0, 200 tM TM alone; 0, 200gM
TM + 300fiM NU1025. Single data points are shown from
representative experiments, where TM ± PADPRP inhibitor
treatments were carried out in parallel.
1Potentiation oftemozolomidecytotoxicity
S Boulton etal
855
maintained in intact cells when the cellular responses to
DNA damage known to be modulated by PADPRP function
(i.e. cytotoxicity and DNA repair) are investigated. Further-
more, there is more than an order of magnitude difference in
the concentration of PD 128763 and NU1025 (10-50I1M)
required to potentiate TM cytotoxicity compared with the
concentrations of the compounds alone required to exert
cytotoxic effects (> 1 mM). In comparison, considerable over-
lap is evident in the concentrations of 3AB and BZ required
to exert these two effects. Thus, there is a bigger gap between
the synergistic enhancement of cytotoxicity and the indepen-
dent toxicity of the new inhibitors compared with 3AB and
BZ, indicative of improved specificity.
It has not escaped our notice that the data presented here
suggest a dissociation between the effect of PADPRP
inhibitors on cell survival and their effect on DNA strand
break repair. For example, significant potentiation of TM
cytotoxicity is obtained with PD 128763 at 10 9M, and has
reached its maximum by 50gM (see Figure 4). In contrast,
PD 128763 does not affect TM-induced DNA strand break
levels significantly until concentrations of > 100 LM are
reached (Figure 7). A plausible explanation for these obser-
vations is that PADPRP mediates not only DNA repair
processes, but also independently modulates DNA damage-
inducible responses involved in cell survival (e.g. specific gene
transcription, p53 stabilisation; Kastan et al., 1991). The
difference in the concentrations of inhibitors required would
reflect the degree of inhibition of PADPRP necessary to
modulate these responses. A more detailed analysis of these
observations is currently under way.
In conclusion, PD 128763 and NU1025 can potentiate the
cytotoxicity of clinically relevant concentrations of TM, and
at micromolar compared with millimolar concentrations
required for BZ and 3AB. These are important considera-
tions if the use of these compounds as potentiators of drug-
induced cytotoxicity is to be extrapolated to the clinic. These
data provide the groundwork for initiating in vivo studies to
establish the ability of PADPRP inhibitors, used in conjunc-
tion with chemotherapeutic agents, to enhance tumour
regression.
Abbreviations
3AB, 3-aminobenzamide; BZ, benzamide; IC", concentration which
reduces growth/activity by 50%; DMSO, dimethyl sulphoxide; DBD,
DNA-binding domain; DEF1O, dose enhancement factor at 10%
survival; LD50, dose which reduces survival by 50% (lethal dose);
MTIC, 5-(3-methyl-triazen-1-yl) imidazole-4-carboxamide; PBS,
phosphate-buffered saline; PADPRP, poly(ADP-ribose) polymerase;
RE, relative elution; RR, relative retention; TM, temozolomide; s.e.,
standard error.
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